1. Scrip
  2. >>Therapy Areas

AbbVie/J&J Withdrawal Of Imbruvica Indications Clears Space For Competitors

 
• By Alaric DeArment

The BTK inhibitor’s exit from MCL and MZL after lackluster Phase III confirmatory trial results gives AstraZeneca’s Calquence and BeiGene’s Brukinsa a potential shot at claiming the space.

AbbVie and J&J said they would withdraw two of Imbruvica's lymphoma indications • Source: Shutterstock

The loss of two indications for AbbVie Inc. and Johnson & Johnson’s Imbruvica (ibrutinib), for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), are relatively small markets for the BTK inhibitor, but their withdrawal from Imbruvica’s label potentially clears the way for newer BTK inhibitors, provided their confirmatory trials are more successful.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.